BiotechTube

ONO-7018 + ONO-7018

Phase 1Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lymphoma, Non-Hodgkin

Conditions

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Trial Timeline

Feb 13, 2023 → Dec 1, 2027

NCT ID
NCT05515406

About ONO-7018 + ONO-7018

ONO-7018 + ONO-7018 is a phase 1 stage product being developed by Ono Pharmaceutical for Lymphoma, Non-Hodgkin. The current trial status is active. This product is registered under clinical trial identifier NCT05515406. Target conditions include Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05515406Phase 1Active

Competing Products

20 competing products in Lymphoma, Non-Hodgkin

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
44
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
52
EnzastaurinEli LillyPhase 2
52
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
52
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)Eli LillyPhase 2
52
VIP152 + BTKiVincerx PharmaPhase 1
25
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 1/2
33
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
44
Sepantronium BromideCothera BiosciencePhase 2
44
Copanlisib + RituximabCelltrionPhase 2
52
Rituximab + PembrolizumabCelltrionPhase 2
52
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
rituximabCelltrionPhase 1
33
CT-P10 + RituxanCelltrionPhase 3
77
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + PrednisoneCelltrionPhase 3
77
Rituximab, lenalidomideCelltrionPhase 2
52
Rituximab + Lenalidomide + ValemetostatDaiichi SankyoPhase 1/2
41
Valemetostat tosylateDaiichi SankyoPhase 2
52
PLX3397Daiichi SankyoPhase 2
52
Valemetostat TosylateDaiichi SankyoPhase 2
52

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77